Acuta Capital Partners, LLC Cyma Bay Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $936,577 - $1.81 Million	74,155 Added 17.74%	492,155 $11.6 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $130,320 - $211,440	-12,000 Reduced 2.79%	418,000 $6.23 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $3.35 Million - $4.91 Million	-448,500 Reduced 51.05%	430,000 $4.71 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $802,620 - $1.31 Million	-136,500 Reduced 13.45%	878,500 $7.66 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $3.27 Million - $6.36 Million	1,015,000 New	1,015,000 $6.36 Million
Q4 2021 Feb 14, 2022	SELL	$3.23 - $4.6 $975,149 - $1.39 Million	-301,904 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $52,941 - $66,110	-13,437 Reduced 4.26%	301,904 $1.32 Million
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $62,007 - $96,016	-14,659 Reduced 4.44%	315,341 $1.43 Million
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $2.49 Million - $3.93 Million	-435,000 Reduced 56.86%	330,000 $1.89 Million
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $2.54 Million - $5.54 Million	765,000 New	765,000 $5.54 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $3.13 Million - $7.07 Million	-517,500 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$8.16 - $13.42 $4.22 Million - $6.94 Million	517,500 New	517,500 $6.87 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.